PURPOSE: To estimate the maximum-tolerated dose (MTD), describe dose-limiting toxicities (DLTs), and characterize pharmacokinetic properties of MK-0752, a gamma secretase inhibitor, in children with refractory or recurrent CNS malignancies. PATIENTS AND METHODS: MK-0752 was administered once daily for 3 consecutive days of every 7 days at escalating dosages starting at 200 mg/m(2). The modified continual reassessment method was used to estimate the MTD. A course was 28 days in duration. Pharmacokinetic analysis was performed during the first course. Expression of NOTCH and hairy enhancer of split (HES) proteins was assessed in peripheral-blood mononuclear cells (PBMCs) before and following treatment with MK-0752. RESULTS: Twenty-three eligible patients were enrolled: 10 males (median age, 8.1 years; range, 2.6 to 17.7 years) with diagnoses of brainstem glioma (n = 6), ependymoma (n = 8), medulloblastoma/primitive neuroectodermal tumor (n = 4), glioblastoma multiforme (n = 2), atypical teratoid/rhabdoid tumor (n = 1), malignant glioma (n = 1), and choroid plexus carcinoma, (n = 1). Seventeen patients were fully evaluable for toxicity. No DLTs occurred in the three patients enrolled at 200 mg/m(2)/dose. At 260 mg/m(2)/dose, DLTs occurred in two of six patients, both of whom experienced grade 3 ALT and AST. There were no grade 4 toxicities; non-dose-limiting grade 3 toxicities included hypokalemia and lymphopenia. Population pharmacokinetic values (% coefficient of variation) for MK-0752 were apparent oral clearance, 0.444 (38%) L/h/m(2); apparent volume of distribution, 7.36 (24%) L/m(2); and k(a), 0.358 (99%) hr(-1). CONCLUSION: MK-0752 is well-tolerated in children with recurrent CNS malignancies. The recommended phase II dose using the 3 days on followed by 4 days off schedule is 260 mg/m(2)/dose once daily.
PURPOSE: To estimate the maximum-tolerated dose (MTD), describe dose-limiting toxicities (DLTs), and characterize pharmacokinetic properties of MK-0752, a gamma secretase inhibitor, in children with refractory or recurrent CNS malignancies. PATIENTS AND METHODS: MK-0752 was administered once daily for 3 consecutive days of every 7 days at escalating dosages starting at 200 mg/m(2). The modified continual reassessment method was used to estimate the MTD. A course was 28 days in duration. Pharmacokinetic analysis was performed during the first course. Expression of NOTCH and hairy enhancer of split (HES) proteins was assessed in peripheral-blood mononuclear cells (PBMCs) before and following treatment with MK-0752. RESULTS: Twenty-three eligible patients were enrolled: 10 males (median age, 8.1 years; range, 2.6 to 17.7 years) with diagnoses of brainstem glioma (n = 6), ependymoma (n = 8), medulloblastoma/primitive neuroectodermal tumor (n = 4), glioblastoma multiforme (n = 2), atypical teratoid/rhabdoid tumor (n = 1), malignant glioma (n = 1), and choroid plexus carcinoma, (n = 1). Seventeen patients were fully evaluable for toxicity. No DLTs occurred in the three patients enrolled at 200 mg/m(2)/dose. At 260 mg/m(2)/dose, DLTs occurred in two of six patients, both of whom experienced grade 3 ALT and AST. There were no grade 4 toxicities; non-dose-limiting grade 3 toxicities included hypokalemia and lymphopenia. Population pharmacokinetic values (% coefficient of variation) for MK-0752 were apparent oral clearance, 0.444 (38%) L/h/m(2); apparent volume of distribution, 7.36 (24%) L/m(2); and k(a), 0.358 (99%) hr(-1). CONCLUSION:MK-0752 is well-tolerated in children with recurrent CNS malignancies. The recommended phase II dose using the 3 days on followed by 4 days off schedule is 260 mg/m(2)/dose once daily.
Authors: D G Tubergen; C F Stewart; C B Pratt; W C Zamboni; N Winick; V M Santana; Z A Dryer; J Kurtzberg; B Bell; H Grier; T J Vietti Journal: J Pediatr Hematol Oncol Date: 1996-11 Impact factor: 1.289
Authors: Andrew R Hallahan; Joel I Pritchard; Stacey Hansen; Mark Benson; Jennifer Stoeck; Beryl A Hatton; Thomas L Russell; Richard G Ellenbogen; Irwin D Bernstein; Phillip A Beachy; James M Olson Journal: Cancer Res Date: 2004-11-01 Impact factor: 12.701
Authors: Giovanni Tonon; Sanjay Modi; Lizi Wu; Akihito Kubo; Amy B Coxon; Takefumi Komiya; Kevin O'Neil; Kristen Stover; Adel El-Naggar; James D Griffin; Ilan R Kirsch; Frederic J Kaye Journal: Nat Genet Date: 2003-01-21 Impact factor: 38.330
Authors: Amar Gajjar; Roberto Hernan; Mehmet Kocak; Christine Fuller; Youngsoo Lee; Peter J McKinnon; Dana Wallace; Ching Lau; Murali Chintagumpala; David M Ashley; Stewart J Kellie; Larry Kun; Richard J Gilbertson Journal: J Clin Oncol Date: 2004-02-17 Impact factor: 44.544
Authors: John C Panetta; Mark N Kirstein; Amar Gajjar; Geeta Nair; Maryam Fouladi; Richard L Heideman; Mark Wilkinson; Clinton F Stewart Journal: Cancer Chemother Pharmacol Date: 2003-09-16 Impact factor: 3.333
Authors: Lindsey M Hoffman; Maryam Fouladi; James Olson; Vinay M Daryani; Clinton F Stewart; Cynthia Wetmore; Mehmet Kocak; Arzu Onar-Thomas; Lars Wagner; Sridharan Gururangan; Roger J Packer; Susan M Blaney; Amar Gajjar; Larry E Kun; James M Boyett; Richard J Gilbertson Journal: Childs Nerv Syst Date: 2015-05-01 Impact factor: 1.475